Oncoinvent Announces Advancement of Radspherin[® ]to Second Dose Level Cohort in Ongoing Phase 1 Trial
Safety Monitoring Committee review of first dose-level cohort allows progression of RAD-18-001 study to second dose level cohortOslo 30. November 2020 Oncoinvent AS, a clinical stage radiopharmaceutical company developing novel radioisotope-based therapies, today announced that the trial Safety Monitoring Committee approved the advancement of the study to the second level dose cohort of the company’s first-in-human Phase 1 clinical study of Radspherin[®, ]RAD-18-001, in ovarian cancer patients suffering from peritoneal carcinomatosis. Enrollment in this cohort, where patients will